Hedgehog signaling pathway inhibitors: an updated patent review (2015–present)

References

• Ingham PW, Nakano Y, Seger C. Mechanisms and functions of Hedgehog signalling across the metazoa. Nat Rev Genet. 2011;12(6):393–406.
   PubMed Web of Science ®Google Scholar
• Infante P, Faedda R, Bernardi F, et al. Itch/beta-arrestin2-dependent non-proteolytic ubiquitylation of SuFu controls Hedgehog signalling and medulloblastoma tumorigenesis. Nat Commun. 2018;9:976. DOI: 10.1038/s41467-018-03339-0.
   Web of Science ®Google Scholar
• Briscoe J, Therond PP. The mechanisms of Hedgehog signalling and its roles in development and disease. Nat Rev Mol Cell Bio. 2013;14(7):416–429.
   PubMed Web of Science ®Google Scholar
• Hui CC, Angers S. Gli proteins in development and disease. Annu Rev Cell Dev Biol. 2011;27:513–537.
   PubMed Web of Science ®Google Scholar
• Kogerman P, Grimm T, Kogerman L, et al. Mammalian Suppressor-of-Fused modulates nuclear-cytoplasmic shuttling of GLI-1. Nat Cell Biol. 1999;1(5):312–319.
   PubMed Web of Science ®Google Scholar
• Ingham PW, McMahon AP. Hedgehog signaling in animal development: paradigms and principles. Gene Dev. 2001;15(23):3059–3087.
   PubMed Web of Science ®Google Scholar
• Zhang JY, Tian XJ, Xing JH. Signal transduction pathways of EMT Induced by TGF-, SHH, and WNT and their crosstalks. J Clin Med. 2016;5(4):41.
   Web of Science ®Google Scholar
• Buonamici S, Williams J, Morrissey M, et al. Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma. Sci Transl Med. 2010;2(51):51ra70-51ra70.
   PubMed Web of Science ®Google Scholar
• Atwood SX, Li MC, Lee A, et al. GLI activation by atypical protein kinase C ι/λ regulates the growth of basal cell carcinomas. Nature. 2013;494(7438):484–488.
   PubMed Web of Science ®Google Scholar
• Pietrobono S, Gagliardi S, Stecca B. Non-canonical Hedgehog signaling pathway in cancer: activation of GLI transcription factors beyond smoothened. Front Genet. 2019;10:556.
   Web of Science ®Google Scholar
• Wang Y, Ding QQ, Yen CJ, et al. The crosstalk of mTOR/S6K1 and Hedgehog pathways. Cancer Cell. 2012;21(3):374–387.
   PubMed Web of Science ®Google Scholar
• Colavito SA, Zou MR, Yan Q, et al. Significance of glioma-associated oncogene homolog 1 (GLI1) expression in claudin-low breast cancer and crosstalk with the nuclear factor kappa-light-chain-enhancer of activated B cells (NF kappa B) pathway. Breast Cancer Res. 2014;16(5):444.
   PubMed Web of Science ®Google Scholar
• Skoda AM, Simovic D, Karin V, et al. The role of the Hedgehog signaling pathway in cancer: a comprehensive review. Bosnian J Basic Med. 2018;18(1):8–20.
   PubMed Web of Science ®Google Scholar
• Harris LG, Samant RS, Shevde LA. Hedgehog signaling: networking to nurture a promalignant tumor microenvironment. Mol Cancer Res. 2011;9(9):1165–1174.
   PubMed Web of Science ®Google Scholar
• Tian H, Callahan CA, DuPree KJ, et al. Hedgehog signaling is restricted to the stromal compartment during pancreatic carcinogenesis. Proc Natl Acad Sci U S A. 2009;106(11):4254–4259.
   PubMed Web of Science ®Google Scholar
• Bailey JM, Mohr AM, Hollingsworth MA. Sonic hedgehog paracrine signaling regulates metastasis and lymphangiogenesis in pancreatic cancer. Oncogene. 2009;28(40):3513–3525.
   PubMed Web of Science ®Google Scholar
• Heller E, Hurchla MA, Xiang JY, et al. Hedgehog signaling inhibition blocks growth of resistant tumors through effects on tumor microenvironment. Cancer Res. 2012;72(4):897–907.
   PubMed Web of Science ®Google Scholar
• Das S, Samant RS, Shevde LA. The Hedgehog pathway conditions the bone microenvironment for osteolytic metastasis of breast cancer. Int J Breast Cancer. 2012;2012:1–9.
   PubMedGoogle Scholar
• Feldmann G, Dhara S, Fendrich V, et al. Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: a new paradigm for combination therapy in solid cancers. Cancer Res. 2007;67(5):2187–2196.
   PubMed Web of Science ®Google Scholar
• Souzaki M, Kubo M, Kai M, et al. Hedgehog signaling pathway mediates the progression of non-invasive breast cancer to invasive breast cancer. Cancer Sci. 2011;102(2):373–381.
   PubMed Web of Science ®Google Scholar
• Wang K, Pan L, Che XM, et al. Sonic Hedgehog/GLI1 signaling pathway inhibition restricts cell migration and invasion in human gliomas. Neurol Res. 2010;32(9):975–980.
   PubMed Web of Science ®Google Scholar
• Hochman E, Castiel A, Jacob-Hirsch J, et al. Molecular pathways regulating pro-migratory effects of Hedgehog signaling. J Biol Chem. 2006;281(45):33860–33870.
   PubMed Web of Science ®Google Scholar
• Stecca B, Mas C, Clement V, et al. Melanomas require HEDGEHOG-GLI signaling regulated by interactions between GLI1 and the RAS-MEK/AKT pathways. Proc Natl Acad Sci U S A. 2007;104(14):5895–5900.
   PubMed Web of Science ®Google Scholar
• Chen WW, Tang T, Eastham-Anderson J, et al. Canonical hedgehog signaling augments tumor angiogenesis by induction of VEGF-A in stromal perivascular cells. Proc Natl Acad Sci U S A. 2011;108(23):9589–9594.
   PubMed Web of Science ®Google Scholar
• Infante P, Alfonsi R, Ingallina C, et al. Inhibition of Hedgehog-dependent tumors and cancer stem cells by a newly identified naturally occurring chemotype. Cell Death Dis. 2016;7:e2376.
   Web of Science ®Google Scholar
• Ghirga F, Mori M, Infante P. Current trends in Hedgehog signaling pathway inhibition by small molecules. Bioorg Med Chem Lett. 2018;28(19):3131–3140.
   PubMed Web of Science ®Google Scholar
• Palermo R, Ghirga F, Piccioni MG, et al. Natural products inspired modulators of cancer stem cells-specific signaling pathways notch and Hedgehog. Curr Pharm Design. 2018;24(36):4251–4269.
   PubMed Web of Science ®Google Scholar
• Zhang H, Sun ZJ, Liu ZP, et al. Overcoming the emerging drug resistance of smoothened: an overview of small-molecule SMO antagonists with antiresistance activity. Future Med Chem. 2018;10(24):2855–2876.
   PubMed Web of Science ®Google Scholar
• Atwood SX, Sarin KY, Whitson RJ, et al. Smoothened variants explain the majority of drug resistance in basal cell carcinoma. Cancer Cell. 2015;27(3):342–353.
   PubMed Web of Science ®Google Scholar
• Danial C, Sarin KY, Oro AE, et al. An investigator-initiated open-label trial of Sonidegib in advanced basal cell carcinoma patients resistant to Vismodegib. Clin Cancer Res. 2016;22(6):1325–1329.
   PubMed Web of Science ®Google Scholar
• Wang C, Wu HX, Katritch V, et al. Structure of the human smoothened receptor bound to an antitumour agent. Nature. 2013;497(7449):338.
   PubMed Web of Science ®Google Scholar
• Hoch L, Faure H, Roudaut H, et al. MRT-92 inhibits Hedgehog signaling by blocking overlapping binding sites in the transmembrane domain of the Smoothened receptor. Faseb J. 2015;29(5):1817–1829.
   PubMed Web of Science ®Google Scholar
• Alfonsi R, Botta B, Cacchi S, et al. Design, palladium-catalyzed synthesis, and biological investigation of 2-substituted 3-Aroylquinolin-4(1H)-ones as inhibitors of the Hedgehog signaling pathway. J Med Chem. 2017;60(4):1469–1477.
   PubMed Web of Science ®Google Scholar
• Lauressergues E, Heusler P, Lestienne F, et al. Pharmacological evaluation of a series of smoothened antagonists in signaling pathways and after topical application in a depilated mouse model. Pharmacol Res Perspect. 2016;4(2):e00214.
   PubMed Web of Science ®Google Scholar
• D’Amato C, Rosa R, Marciano R, et al. Inhibition of Hedgehog signalling by NVP-LDE225 (Erismodegib) interferes with growth and invasion of human renal cell carcinoma cells. Br J Cancer. 2014;111(6):1168–1179.
   PubMed Web of Science ®Google Scholar
• Peer E, Tesanovic S, Aberger F. Next-generation Hedgehog/GLI Pathway Inhibitors for Cancer Therapy. Cancers (Basel). 2019;11(4):538.
   PubMed Web of Science ®Google Scholar
• Infante P, Alfonsi R, Botta B, et al. Targeting GLI factors to inhibit the Hedgehog pathway. Trends Pharmacol Sci. 2015;36(8):547–558.
   PubMed Web of Science ®Google Scholar
• Infante P, Mori M, Alfonsi R, et al. Gli1/DNA interaction is a druggable target for Hedgehog-dependent tumors. Embo J. 2015;34(2):200–217.
   PubMed Web of Science ®Google Scholar
• Pandolfi S, Stecca B. Cooperative integration between HEDGEHOG-GLI signalling and other oncogenic pathways: implications for cancer therapy. Expert Rev Mol Med. 2015;17:e5.
   PubMed Web of Science ®Google Scholar
• Calcaterra A, Iovine V, Botta B, et al. Chemical, computational and functional insights into the chemical stability of the Hedgehog pathway inhibitor GANT61. J Enzyme Inhib Med Chem. 2018;33(1):349–358.
   PubMed Web of Science ®Google Scholar
• Didiasova M, Schaefer L, Wygrecka M. Targeting GLI transcription factors in cancer. Molecules. 2018;23(5):1003.
   PubMed Web of Science ®Google Scholar
• Berardozzi S, Bernardi F, Infante P, et al. Synergistic inhibition of the Hedgehog pathway by newly designed Smo and Gli antagonists bearing the isoflavone scaffold. Eur J Med Chem. 2018;156:554–562.
   PubMed Web of Science ®Google Scholar
• Lospinoso Severini L, Quaglio D, Basili I, et al. A Smo/Gli multitarget hedgehog pathway inhibitor impairs tumor growth. Cancers (Basel). 2019;11(10):1518.
   PubMed Web of Science ®Google Scholar
• Bufalieri F, Infante P, Bernardi F, et al. ERAP1 promotes Hedgehog-dependent tumorigenesis by controlling USP47-mediated degradation of beta TrCP. Nat Commun. 2019;10:3304.
   Web of Science ®Google Scholar
• Memorial Sloan-Kettering cancer center, Tri-institutional therapeutics discovery institute Inc. Hedgehog acyltransferase inhibitors and uses thereof. WO2017218874A1. 2017.
   Google Scholar
• Memorial Sloan-Kettering Cancer Center, Rockefeller University. Treatment of pancreatic and related cancers with 5-acyl-6,7-dihydrothieno[3,2-c]pyridines. WO142253. 2013.
   Google Scholar
• Rodgers UR, Lanyon-Hogg T, Masumoto N, et al. Characterization of Hedgehog acyltransferase inhibitors identifies a small molecule probe for hedgehog signaling by cancer cells. Acs Chem Biol. 2016;11(12):3256–3262.
   PubMed Web of Science ®Google Scholar
• Owens AE, de Paola I, Hansen WA, et al. Design and evolution of a macrocyclic peptide inhibitor of the Sonic Hedgehog/patched interaction. J Am Chem Soc. 2017;139(36):12559–12568.
   PubMed Web of Science ®Google Scholar
• University of Rochester. Cyclic peptide inhibitors of Hedgehog proteins. WO2017223207. 2017.
   Google Scholar
• Stanton BZ, Peng LF, Maloof N, et al. A small molecule that binds Hedgehog and blocks its signaling in human cells. Nat Chem Biol. 2009;5(3):154–156.
   PubMed Web of Science ®Google Scholar
• Tolani B, Hoang NT, Acevedo LA, et al. Preclinical characterization of therapeutic antibodies targeted at the carboxy-terminus of Sonic hedgehog. Oncotarget. 2018;9(18):14311–14323.
   PubMedGoogle Scholar
• The Regents of the University of California. Antibodies specific to Sonic hedgehog and method of use thereof. WO2018005697. 2018.
   Google Scholar
• Yuan Z, Goetz JA, Singh S, et al. Frequent requirement of hedgehog signaling in non-small cell lung carcinoma. Oncogene. 2007;26(7):1046–1055.
   PubMed Web of Science ®Google Scholar
• Bermudez O, Hennen E, Koch I, et al. Gli1 mediates lung cancer cell proliferation and Sonic Hedgehog-dependent mesenchymal cell activation. Plos One. 2013;8(5):e63226.
   Web of Science ®Google Scholar
• Runping&Partners. Pharmaceutical composition and use thereof and methods of treating diseases mediated by Hedgehog signaling pathway. WO2016191911. 2016.
   Google Scholar
• Suzhou Kintor Pharmaceuticals Inc. Hedgehog pathway signaling inhibitors and therapeutic applications thereof. WO2014113191. 2014.
   Google Scholar
• Suzhou Kintor Pharmaceuticals Inc. Chiral heterocyclic compound with Hedgehog pathway antagonist activity, method and use thereof. WO2018006756. 2018.
   Google Scholar
• Tetra Bio-Pharma Inc. Compositions comprising cannabinoids and terpenes useful in the treatment of cancer and vascular ocular disorders via inhibition of Hedgehog signalling. WO2018205038. 2018.
   Google Scholar
• Khaliullina H, Bilgin M, Sampaio JL, et al. Endocannabinoids are conserved inhibitors of the Hedgehog pathway. Proc Natl Acad Sci U S A. 2015;112(11):3415–3420.
   PubMed Web of Science ®Google Scholar
• Max-Planck-Gesellschaft zur Forderung der Wissenschaften E.V. Cannabinoids for the treatment of cancers dependent on Hedgehog mechanisms. WO2014057067. 2014.
   Google Scholar
• Williams CH, Hempel JE, Hao J, et al. An in vivo chemical genetic screen identifies phosphodiesterase 4 as a pharmacological target for hedgehog signaling inhibition. Cell Rep. 2015;11(1):43–50.
   PubMed Web of Science ®Google Scholar
• Hempel JE, Cadar AG, Hong CC. Development of thieno- and benzopyrimidinone inhibitors of the Hedgehog signaling pathway reveals PDE4-dependent and PDE4-independent mechanisms of action. Bioorg Med Chem Lett. 2016;26(8):1947–1953.
   PubMed Web of Science ®Google Scholar
• Vanderbilt University. Compounds and methods for inhibition of Hedgehog signaling and phosphodiesterase. US20170190717. 2017.
   Google Scholar
• Max Biopharma Inc. Oxysterols and Hedgehog signaling. WO2017074957. 2017.
   Google Scholar
• Wang F, Stappenbeck F, Parhami F. Inhibition of Hedgehog signaling in fibroblasts, pancreatic, and lung tumor cells by Oxy186, an oxysterol analogue with drug-like properties. Cells. 2019;8(5):509.
   Web of Science ®Google Scholar
• Redx Pharma Plc. Heterocyclic compounds as Hedgehog signaling pathway inhibitors. WO2014191737. 2014.
   Google Scholar
• Astex Technology Limited. Benzimidazole derivatives and their use as Hedgehog signalling pathway inhibitors. GB2519344. 2015.
   Google Scholar
• Redx Pharma Plc. Pyridazine derivatives as Hedgehog pathway inhibitors. WO2015001348. 2015.
   Google Scholar
• Ltd Guangdong Zhongsheng Pharmaceutical Co. Quinoline derivatives as Smo inhibitors. CA2943100.2015.
   Google Scholar
• Leadiant Biosciences SA. Gli1 inhibitors and uses thereof. EP3388419. 2017.
   Google Scholar
• University of Connecticut. Azole analogues and methods of use thereof. WO2019040363. 2019.
   Google Scholar
• University of Connecticut. Itraconazole analogues and methods of use thereof. WO2015116947. 2015.
   Google Scholar
• Teske KA, Dash RC, Morel SR, et al. Development of posaconazole-based analogues as hedgehog signaling pathway inhibitors. Eur J Med Chem. 2019;163:320–332.
   PubMed Web of Science ®Google Scholar
• Wen J, Teske KA, Hadden MK. Inhibition of Hedgehog signaling by stereochemically defined des-triazole itraconazole analogues. Bioorg Med Chem Lett. 2020;30(2):126794.
   PubMed Web of Science ®Google Scholar
• Wen JC, Chennamadhavuni D, Morel SR, et al. Truncated Itraconazole analogues exhibiting potent anti-Hedgehog activity and improved drug-like properties. Acs Med Chem Lett. 2019;10(9):1290–1295.
   PubMed Web of Science ®Google Scholar
• Pace JR, Teske KA, Chau LQ, et al. Structure-activity relationships for Itraconazole-based triazolone analogues as hedgehog pathway inhibitors. J Med Chem. 2019;62(8):3873–3885.
   PubMed Web of Science ®Google Scholar
• Pace JR, DeBerardinis AM, Sail V, et al. Repurposing the clinically efficacious antifungal agent Itraconazole as an anticancer chemotherapeutic. J Med Chem. 2016;59(8):3635–3649.
   PubMed Web of Science ®Google Scholar
• Pace JR, Jog R, Burgess DJ, et al. Formulation and evaluation of itraconazole liposomes for Hedgehog pathway inhibition. J Liposome Res. 2019:1–7.
   PubMed Web of Science ®Google Scholar
• Development Center For Biotechnology. Hetroarylamine compounds for modulating the Hedgehog pathway and preparing method and uses thereof. WO2018098250. 2018.
   Google Scholar
• E-Therapeutics Plc. Modulators of Hedgehog (Hh) signalling pathway. WO2018078360. 2018.
   Google Scholar
• E-Therapeutics Plc. Substitutes sulfonyl azacycles as modulators of Hedgehog (Hh) signalling pathway. WO2019043372. 2019.
   Google Scholar
• E-Therapeutics Plc. Substituted Cyclic-sulfonamides as modulators of Hedgehog (Hh) signalling pathway. WO2019043373. 2019.
   Google Scholar
• Ingallina C, Costa PM, Ghirga F, et al. Polymeric glabrescione B nanocapsules for passive targeting of Hedgehog-dependent tumor therapy in vitro. Nanomedicine (Lond). 2017;12(7):711–728.
   PubMed Web of Science ®Google Scholar
• D’Alessandro G, Quaglio D, Monaco L, et al. H-1-NMR metabolomics reveals the Glabrescione B exacerbation of glycolytic metabolism beside the cell growth inhibitory effect in glioma. Cell Commun Signal. 2019;17(1):108.
   PubMed Web of Science ®Google Scholar
• Università degli Studi di Roma “La Sapienza”, Fondazione Istituto Italiano di Tecnologia. Compounds for use in the treatment of brain diseases. WO2019149962. 2019.
   Google Scholar
• Università degli Studi di Siena, Università degli Studi di Roma “La Sapienza”. Multitarget Hedgehog pathway inhibitors and uses thereof. WO2014207069. 2014.
   Google Scholar
• Lospinoso Severini L, Quaglio Q, Basili B, et al. A Smo/Gli multitarget Hedgehog pathway inhibitor impairs tumor growth. Cancers (Basel). 2019;11(10):1518.
   Web of Science ®Google Scholar
• Dawood S, Austin L, Cristofanilli M. Cancer stem cells: implications for cancer therapy. Oncology-Ny. 2014;28(12):1101.
   PubMed Web of Science ®Google Scholar